Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 50mg - tapentadol (tapentadol hydrochloride) 50mg

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 75mg - tapentadol (tapentadol hydrochloride) 75mg

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 100mg - tapentadol (tapentadol hydrochloride) 100mg

United States - English - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta er (tapentadol) is indicated for the management of: - pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate - neuropathic pain associated with diabetic peripheral neuropathy (dpn) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve nucynta er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. nucynta er is not indicated as an as-needed (prn) analgesic. - nucynta er is not indicated as an as-neede

United States - English - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve nucynta tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia nucynta tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.5)] - known or suspected gastrointestinal obstruction, including suspected paralytic ileus [see warnings and precauti

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol (unii: h8a007m585) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - 1 indications and usage nucynta® (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. 4 contraindications 4.1 impaired pulmonary function like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . 4.2 paralytic ileus like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. 4.3 monoamine oxidase inhibitors nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which ma

United States - English - NLM (National Library of Medicine)

rebel distributors corp - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w

United States - English - NLM (National Library of Medicine)

stat rx usa - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta™ (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. like other drugs with mu-opioid agonist activity, nucynta™ is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta™ is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta™ is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta™ is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregna

Singapore - English - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. (uen 200411241w) - tapentadol hydrochloride 174.72 mg eqv tapentadol - tablet, film coated - 150 mg - tapentadol hydrochloride 174.72 mg eqv tapentadol 150 mg

Singapore - English - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. (uen 200411241w) - tapentadol hydrochloride 58.24 mg eqv tapentadol - tablet, film coated - 50 mg - tapentadol hydrochloride 58.24 mg eqv tapentadol 50 mg